There are 105 resources available
Q&A live discussion
Presenter: Roy S. Herbst
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Webcast
Invited Discussant LBA54 and LBA55
Presenter: Adrian Sacher
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Roy S. Herbst
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Webcast
CN14 - The utility of a brief clinical frailty scale (CFS) in predicting prognosis and discharge destination in oncology inpatients
Presenter: Jenny Welford
Session: EONS13: Age specific care in oncology: Geriatrics (in collaboration with SIOG)
Resources:
Abstract
Slides
Webcast
CN5 - Video consultations with older patients in the oncology nursing outpatient clinic
Presenter: Karin Dieperink
Session: EONS13: Age specific care in oncology: Geriatrics (in collaboration with SIOG)
Resources:
Abstract
Slides
Webcast
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Presenter: Zeynep Zengin
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Presenter: Sumanta Pal
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
LBA25 - Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Presenter: Yann Vano
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
LBA31 - Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Presenter: Kathleen Moore
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
805O - ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment
Presenter: Andrew Clamp
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast